Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

20.680
+0.0200.10%
Volume:2.86M
Turnover:59.24M
Market Cap:18.03B
PE:60.28
High:20.900
Open:20.660
Low:20.500
Close:20.660
52wk High:30.750
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.72
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.343
ROE:46.90%
ROA:-0.81%
PB:1.89
PE(LYR):60.28
PS:3.85

Loading ...

HUTCHMED (00013) Initiates Global Clinical Development of ATTC Candidate HMPL-A251 for Solid Tumors

Stock News
·
Dec 17

HUTCHMED Launches Global Phase I Trial of Novel ATTC Drug HMPL-A251 for Solid Tumors

Reuters
·
Dec 17

HUTCHMED Initiates Global Clinical Development of Attc Candidate Hmpl-a251 in Patients With Solid Tumors

THOMSON REUTERS
·
Dec 17

China Renews Reimbursement for Three Hutchmed Drugs

MT Newswires Live
·
Dec 08

HUTCHMED (00013): TAZVERIK® Included in the First National Commercial Health Insurance Innovative Drug List

Stock News
·
Dec 08

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

GlobeNewswire
·
Dec 08

BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample

Stock News
·
Dec 05

HUTCHMED (China) Limited (00013) Announces November 2025 Monthly Return

Bulletin Express
·
Dec 01

HUTCHMED (13) Reports Updated Share Capital and Voting Rights

Bulletin Express
·
Nov 28

HUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting

Stock News
·
Nov 27

HUTCHMED Announces New Clinical Data Presentations on Cancer and Hematology Therapies at 2025 ESMO Asia and ASH Meetings

Reuters
·
Nov 27

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

GlobeNewswire
·
Nov 27

HUTCHMED (00013) Narrows YTD Gain to 5%: When Will the "Bull Market Misser" Rebound?

Stock News
·
Nov 12

Orient Securities Maintains "Buy" Rating on HUTCHMED (00013), Highlights Innovative ATTC Platform

Stock News
·
Nov 10

Orient Securities: First Commercial Insurance Drug List Introduced, Policy Support for Innovative Drugs Becomes Clearer

Stock News
·
Nov 07

CICC Maintains Outperform Rating on HUTCHMED (00013) with Target Price of HK$30

Stock News
·
Nov 07

HUTCHMED Completes Enrollment for Global Phase 3 Study of Lung Cancer Combination Therapy

MT Newswires Live
·
Nov 05

HUTCHMED (00013) Completes Patient Enrollment for Global Phase III SAFFRON Study Evaluating ORPATHYS® (Savolitinib) and TAGRISSO® (Osimertinib) Combination Therapy in MET-Overexpressed/Amplified NSCLC Post-TAGRISSO® Progression

Stock News
·
Nov 05

HUTCHMED Announces Enrollment Completed of Saffron Global Phase Iii Trial of Orpathys® and Tagrisso® Combination for Certain Lung Cancer Patients With Met Overexpression and/or Amplification After Progression on Tagrisso®

THOMSON REUTERS
·
Nov 05

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®

GlobeNewswire
·
Nov 05